单倍体移植后使用mbIL21体外扩增供者NK细胞的1期临床试验
该1期剂量递增试验在高危髓系恶性肿瘤患者中,于单倍体造血干细胞移植前后输注膜结合IL-21(mbIL21)扩增的供者NK细胞,以确定安全性、可行性和最大耐受剂量。13例入组患者中11例接受了全部3剂NK细胞(每剂1×10^5/kg至1×10^8/kg),未发生输注反应或剂量限制性毒性,所有患者均植入供者细胞。
要点
- 13例入组患者中11例接受了全部3剂计划NK细胞输注,所有NK扩增均达到所需细胞数。
- 未发生输注反应或剂量限制性毒性,所有患者均植入供者细胞。
- 7例(54%)发生1-2级急性GVHD,无3-4级急性GVHD或慢性GVHD,病毒感染并发症发生率低。
核心结论
- 该试验证明在单倍体造血干细胞移植后输注高剂量体外扩增NK细胞具有生产可行性和安全性,未出现不良反应、GVHD增加或死亡率升高,并与NK细胞数量和功能显著改善、病毒感染减少及移植后低复发率相关。
研究设计与样本
- 1期剂量递增研究,在高危髓系恶性肿瘤患者中于单倍体造血干细胞移植前后输注mbIL21扩增的供者NK细胞。
- 患者接受以美法仑为基础的减低强度预处理方案和移植后以环磷酰胺为基础的移植物抗宿主病(GVHD)预防。
- NK细胞在移植后第-2天、+7天和+28天输注,每剂剂量为1×10^5/kg至1×10^8/kg。
主要发现
- 13例入组患者中11例接受了全部3剂计划NK细胞输注,所有NK扩增均达到所需细胞数。
- 未发生输注反应或剂量限制性毒性,所有患者均以供者细胞植入。
- 7例(54%)发生1-2级急性GVHD,无3-4级急性GVHD或慢性GVHD,病毒感染并发症发生率低。
- 1例患者死于非复发死亡,1例患者复发,其余患者末次随访时均存活且处于缓解(中位随访14.7个月)。
- 与未接受NK细胞的类似患者组相比,NK细胞重建在数量、表型和功能上均更优。
关键数值与推荐
- NK细胞每剂剂量范围为1×10^5/kg至1×10^8/kg。
- NK细胞在移植后第-2天、+7天和+28天输注。
- 13例入组患者中11例接受了全部3剂计划NK细胞输注。
- 7例(54%)发生1-2级急性GVHD,无3-4级急性GVHD或慢性GVHD。
- 1例患者死于非复发死亡,1例患者复发,中位随访14.7个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse has emerged as the most important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT). To test the hypothesis that natural killer (NK) cells can decrease the risk of leukemia relapse, we initiated a phase 1 dose-escalation study of membrane-bound interleukin 21 (mbIL21) expanded donor NK cells infused before and after haploidentical HSCT for high-risk myeloid malignancies. The goals were to determine the safety, feasibility, and maximum tolerated dose. Patients received a melphalan-based reduced-intensity conditioning regimen and posttransplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis. NK cells were infused on days -2, +7, and +28 posttransplant. All NK expansions achieved the required cell number, and 11 of 13 patients enrolled received all 3 planned NK-cell doses (1 × 105/kg to 1 × 108/kg per dose). No infusional reactions or dose-limiting toxicities occurred. All patients engrafted with donor cells. Seven patients (54%) developed grade 1-2 acute GVHD (aGVHD), none developed grade 3-4 aGVHD or chronic GVHD, and a low incidence of viral complications was observed. One patient died of nonrelapse mortality; 1 patient relapsed. All others were alive and in remission at last follow-up (median, 14.7 months). NK-cell reconstitution was quantitatively, phenotypically, and functionally superior compared with a similar group of patients not receiving NK cells. In conclusion, this trial demonstrated production feasibility and safety of infusing high doses of ex vivo-expanded NK cells after haploidentical HSCT without adverse effects, increased GVHD, or higher mortality, and was associated with significantly improved NK-cell number and function, lower viral infections, and low relapse rate posttransplant.
引用
- Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017. PMID: 28835441. doi:10.1182/blood-2017-05-785659
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。